BCM
MIST icon

Bayesian Capital Management’s Milestone Pharmaceuticals MIST Stock Holding History

Bayesian Capital Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,015
Closed -$11.9K – 272
2026
Q1 		$11.9K Sell
10,015
-7,200
-42% -$12.6K 0.01% 137
2025
Q4 		$34.8K Buy
+17,215
New +$37.1K 0.08% 108

Other funds holding MIST

PCM
Pavaki Capital Management Pueblo, Colorado $287M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Bayesian Capital Management's MIST Position: Q2 2026 in Review

Bayesian Capital Management sold out of Milestone Pharmaceuticals (MIST) in Q2 2026, closing a stake of 10,015 shares — an estimated $11.9K sold.

Bayesian Capital Management first reported a position in MIST in Q4 2025 and held it in 2 quarters. The position peaked at $34.8K in Q4 2025. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Bayesian Capital Management reported no remaining Milestone Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Bayesian Capital Management sold 10,015 Milestone Pharmaceuticals shares in Q2 2026, an estimated $11.9K.
  • Bayesian Capital Management first reported a position in Milestone Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Bayesian Capital Management's Milestone Pharmaceuticals position peaked at $34.8K in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.